18 March 2022 - The considerable unmet need in this patient population means oral mobocertinib has been granted an Innovation Passport by the MHRA, enabling participation and approval via Project Orbis, an international programme that reviews and approves promising cancer drugs to help patients access treatments faster.

Takeda is pleased to announce that the MHRA has granted a conditional marketing authorisation to Exkivity (mobocertinib) in Great Britain as a monotherapy treatment for adult patients with epidermal growth factor receptor exon 20 insertion mutation positive locally advanced or metastatic non-small-cell lung cancer, who have received prior platinum-based chemotherapy.

Read Takeda press release